Myriad Genetics

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Key Points: 
  • SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
  • Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F

Retrieved on: 
Tuesday, February 27, 2024

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its fourth quarter and full-year ended December 31, 2023 and provided its outlook on business performance for its first quarter and full-year 2024.

Key Points: 
  • GAAP operating expenses in the fourth quarter of 2023 were $166.4 million, decreasing $9.7 million year-over-year.
  • Adjusted operating expenses in the fourth quarter of 2023 decreased $8.6 million year-over-year to $130.0 million, reflecting incremental cost control measures during the fourth quarter 2023.
  • GAAP operating loss in the fourth quarter of 2023 was $31.4 million, improving $20.8 million year-over-year; adjusted operating income in the fourth quarter of 2023 was $5.7 million, improving $19.6 million year-over-year from adjusted operating loss of $13.9 million in the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP cash flow from operations was $(55) million; adjusted cash flow from operations in the fourth quarter of 2023 was $14 million, an increase of $10 million year-over-year.

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Retrieved on: 
Tuesday, February 27, 2024

Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.

Key Points: 
  • Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.
  • The goal of SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective, clinical evidence showing MRD testing can be broadly applied across cancer types and to patients with different disease severity or staging.
  • “First generation MRD tests have made remarkable progress monitoring disease recurrence and progression in cancer types with high tumor or variant burden.
  • “We’ve designed Precise MRD to be highly sensitive for application across all cancer types and look forward to this study demonstrating its utility in cancer care.”

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Retrieved on: 
Thursday, February 15, 2024

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.

Key Points: 
  • SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
  • Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad.
  • “We’re thrilled to welcome Dallas to the Myriad team.
  • She is a passionate women’s health leader and patient advocate who is committed to advancing diversity, equity and inclusion in clinical care and education,” said Melissa Gonzales, president of women’s health, Myriad Genetics.

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Retrieved on: 
Tuesday, January 30, 2024

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.

Key Points: 
  • SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.
  • Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients.
  • He is an accomplished healthcare leader with a proven ability to spearhead and manage the development of precision medicine and clinical research programs in the oncology space,” said Paul J. Diaz, president and CEO, Myriad Genetics.
  • “We are delighted for George to join Myriad to lead our oncology commercial and clinical strategy as we continue to expand our oncology portfolio,” said Mark Verratti, Chief Commercial Officer, Myriad Genetics.

BGB Group Announces Partnership with Scrum50 to Deliver High-Impact, Consumer-Centric Creative to Healthcare Clients

Retrieved on: 
Thursday, February 1, 2024

BGB Group (BGB), an award-winning healthcare commercialization and communications company headquartered in New York City with offices in Washington DC, Boston, and London, today announced a strategic partnership with Scrum50 (S50), a dynamic, agile-first creative agency based in South Norwalk, CT.

Key Points: 
  • BGB Group (BGB), an award-winning healthcare commercialization and communications company headquartered in New York City with offices in Washington DC, Boston, and London, today announced a strategic partnership with Scrum50 (S50), a dynamic, agile-first creative agency based in South Norwalk, CT.
  • This collaboration marks a transformative alliance, the next phase of BGB’s expertise enhancement aimed at remaining ahead of biopharma’s biggest challenges.
  • The teams are set to redefine creativity and impact in the healthcare sector.
  • “We are excited to formalize our partnership with S50,” noted Greg Passaretti, Founding Partner of BGB Group.

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Retrieved on: 
Thursday, January 18, 2024

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.

Key Points: 
  • SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.
  • By bringing the Precise Tumor and Precise Liquid tests in house, Myriad will open up new opportunities for innovation, growth, and continued development of its oncology portfolio.
  • Upon the closing of the acquisition on February 1, 2024, Myriad expects to operate TheraMap: Solid Tumor solely as Precise Tumor.
  • The financial terms of the deal were not disclosed but are not material to either Myriad or Intermountain Healthcare.

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Retrieved on: 
Tuesday, January 9, 2024

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.

Key Points: 
  • SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.
  • Among the guidance includes:
    All patients with a current or previous diagnosis of invasive breast cancer ≤ 65 years should be offered BRCA1/2 testing.
  • Patients undergoing genetic testing should be given sufficient information before testing to provide informed consent.
  • “ASCO-SSO’s guideline update is an important step forward in advancing the use of genomics in clinical care for patients with breast cancer,” said Shelly Cummings, Vice President of Oncology Medical Affairs, Myriad Genetics.

Mesa Laboratories Appoints Mark Capone to its Board of Directors

Retrieved on: 
Monday, January 8, 2024

LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.

Key Points: 
  • LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.
  • Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: “We are pleased to welcome Mark to Mesa’s Board.
  • Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics.
  • “I am honored to be joining the Board of Mesa – a high growth life sciences tools organization built around a vision to Protect the Vulnerable,” said Mark Capone.

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Retrieved on: 
Thursday, December 21, 2023

Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring.

Key Points: 
  • Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring.
  • Riggsbee will continue as a strategic advisor through March 31, 2024, to ensure a smooth transition.
  • Leffler has held numerous financial leadership positions and brings expertise in finance transformation, acquisitions and integrations, as well as risk management.
  • At its third quarter 2023 earnings call on November 6, Myriad updated its 2023 financial guidance and introduced 2024 revenue guidance.